213 related articles for article (PubMed ID: 33149225)
1. Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia.
Vinhaes CL; Teixeira RS; Monteiro-Júnior JAS; Tibúrcio R; Cubillos-Angulo JM; Arriaga MB; Sabarin AG; de Souza AJ; Silva JJ; Lyra IM; Ladeia AM; Andrade BB
Sci Rep; 2020 Nov; 10(1):18982. PubMed ID: 33149225
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.
Renó CO; Barbosa AR; de Carvalho SS; Pinheiro MB; Rios DR; Cortes VF; Barbosa LA; Santos HL
Ann Hematol; 2020 May; 99(5):937-945. PubMed ID: 32166377
[TBL] [Abstract][Full Text] [Related]
3. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
Silva DG; Belini Junior E; Torres Lde S; Ricci Júnior O; Lobo Cde C; Bonini-Domingos CR; de Almeida EA
Blood Cells Mol Dis; 2011 Jun; 47(1):23-8. PubMed ID: 21489839
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome.
Connes P; Möckesch B; Tudor Ngo Sock E; Hardy-Dessources MD; Reminy K; Skinner S; Billaud M; Nader E; Tressieres B; Etienne-Julan M; Guillot N; Lemonne N; Hue O; Romana M; Antoine-Jonville S
Eur J Haematol; 2021 Jun; 106(6):800-807. PubMed ID: 33629431
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway.
Nader E; Grau M; Fort R; Collins B; Cannas G; Gauthier A; Walpurgis K; Martin C; Bloch W; Poutrel S; Hot A; Renoux C; Thevis M; Joly P; Romana M; Guillot N; Connes P
Nitric Oxide; 2018 Dec; 81():28-35. PubMed ID: 30342855
[TBL] [Abstract][Full Text] [Related]
7. Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.
Silva DG; Belini Junior E; Carrocini GC; Torres Lde S; Ricci Júnior O; Lobo CL; Bonini-Domingos CR; de Almeida EA
BMC Med Genet; 2013 Oct; 14():108. PubMed ID: 24106994
[TBL] [Abstract][Full Text] [Related]
8. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA
Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932
[TBL] [Abstract][Full Text] [Related]
10. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients.
Torous DK; Avlasevich S; Bemis JC; Howard T; Ware RE; Fung C; Chen Y; Sahsrabudhe D; MacGregor JT; Dertinger SD
Environ Mol Mutagen; 2023 Mar; 64(3):167-175. PubMed ID: 36841969
[TBL] [Abstract][Full Text] [Related]
11. Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia.
Teixeira RS; Terse-Ramos R; Ferreira TA; Machado VR; Perdiz MI; Lyra IM; Nascimento VL; Boa-Sorte N; Andrade BB; Ladeia AM
PLoS One; 2017; 12(9):e0184076. PubMed ID: 28863145
[TBL] [Abstract][Full Text] [Related]
12. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
[TBL] [Abstract][Full Text] [Related]
13. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
14. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
Ware RE; Despotovic JM; Mortier NA; Flanagan JM; He J; Smeltzer MP; Kimble AC; Aygun B; Wu S; Howard T; Sparreboom A
Blood; 2011 Nov; 118(18):4985-91. PubMed ID: 21876119
[TBL] [Abstract][Full Text] [Related]
16. Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-Brazil.
Gonçalves RP; Elias DB; Magalhães HI; de Souza JH
J Clin Lab Anal; 2011; 25(5):369-73. PubMed ID: 21919074
[TBL] [Abstract][Full Text] [Related]
17. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
18. The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia.
Elchuri SV; Williamson RS; Clark Brown R; Haight AE; Spencer JB; Buchanan I; Hassen-Schilling L; Brown MR; Mertens AC; Meacham LR
Blood Cells Mol Dis; 2015 Jun; 55(1):56-61. PubMed ID: 25976468
[TBL] [Abstract][Full Text] [Related]
19. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
Heeney MM; Howard TA; Zimmerman SA; Ware RE
J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
[TBL] [Abstract][Full Text] [Related]
20. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
